Processa Pharmaceuticals

Yahoo Finance • 2 months ago

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it... Full story

Yahoo Finance • 3 months ago

Processa Pharmaceuticals to reconvene annual meeting after achieving quorum

Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), a micro-cap pharmaceutical company with a market capitalization of $5.61 million, will reconvene its Annual Shareholder Meeting on Thursday in Hanover, Maryland, after obtaining a sufficient n... Full story

Yahoo Finance • 3 months ago

Processa Pharmaceuticals adjourns annual meeting due to lack of quorum

Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), a micro-cap pharmaceutical company with a market value of $5.39 million, adjourned its annual shareholder meeting on Monday in Hanover, Maryland, after failing to reach a quorum. The company a... Full story

Yahoo Finance • 3 months ago

Processa Pharmaceuticals price target lowered to $2 at H.C. Wainwright

Investing.com - H.C. Wainwright lowered its price target on Processa Pharmaceuticals (NASDAQ:PCSA) stock to $2.00 from $6.00 on Monday, while maintaining a Buy rating on the shares. The stock, currently trading at $0.20, has declined ove... Full story

Yahoo Finance • 4 months ago

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (the Company), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced the pricing of a publ... Full story

Yahoo Finance • 4 months ago

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that members of its executive leade... Full story

Yahoo Finance • 4 months ago

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today ann... Full story

Yahoo Finance • 8 months ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved eff... Full story

Yahoo Finance • 8 months ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with... Full story

Yahoo Finance • 8 months ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with... Full story

Yahoo Finance • 2 years ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

HANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to im... Full story

Yahoo Finance • 2 years ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs t... Full story

Yahoo Finance • 2 years ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Hanover, MD., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023. Mr. Thompson served on our Boa... Full story

Yahoo Finance • 2 years ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

HANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to im... Full story

Yahoo Finance • 2 years ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Company To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-Cap HANOVER, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq... Full story

Yahoo Finance • 2 years ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to im... Full story

Yahoo Finance • 2 years ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

HANOVER, MD, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to i... Full story

Yahoo Finance • 2 years ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Interim analysis of Phase 1B data suggests Processa’snovel chemotherapy treatmentcould improve safety and efficacy in more patients by individualizing the dosing regimen for each patient HANOVER, MD, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Pr... Full story

Yahoo Finance • 2 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

HANOVER, MD, June 14, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs t... Full story

Yahoo Finance • 2 years ago

Longeveron Welcomes Three New Prominent Board Members

Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of Stockholders MIAMI, June 13, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Lon... Full story